摘要
目的:探讨前列腺特异性膜抗原(PSMA)对于前列腺良恶性疾病的诊断价值。方法:采用实时荧光定量PCR方法检测前列腺癌患者(前列腺癌组,63例)、良性前列腺增生患者(良性前列腺增生组,99例)及健康者(正常对照组,33例)血液中PSMA的相对表达量,并分析3组之间的差异。结果:3组间PSMA相对表达量存在差异(P<0.05),良性前列腺增生组、前列腺癌组均低于正常组(P<0.05),前列腺癌组高于良性前列腺增生组(P<0.05),良性前列腺增生组、前列腺癌组PSMA相对表达量与血清总前列腺特异性抗原TPSA不具相关性(P>0.05)。结论:实时荧光定量PCR检测外周血PSMA可用于区分前列腺癌与良性前列腺增生,但单纯检测外周血PSMA尚无法准确区分出前列腺疾病与健康对照人群,仅可作为一种辅助和补充检测手段。
Objective：To determine the diagnostic yield of prostate specific membrane antigen （PSMA） for the diagnosis of benign or malignant prostate diseases. Methods： The relative expression of serum PSMA was assayed in patients with prostate carcinoma （ group PCa, n = 63 ） , benign prostate hypertrophy （ group BPH, n = 99） and healthy controls （control group, n = 33 ） by using real-time quantitative polymerase chain reaction for further determination of the between-group difference. Results： The between-group difference in PSMA reached statistical significance （ all P 〈 0.05 ）. This was evidenced by the fact that group PCa yielded the highest level of PSMA, followed by group BPH and normal controls （ all P 〈 0.05 ）. However, no correlation between the PSMA expression and serum TPSA was noted in groups PCa and BPH （ both P 〉 0.05 ）. Conclusion： The PSMA in peripheral blood as determined by real-time quantitative PCR may help differentiate prostate carcinoma and benign prostate hypertrophy but could serve as an adjuvant or complementary approach owing to the limited significance for differentiation between patients with prostate diseases and normal controls.
出处
《广州医学院学报》
2012年第6期14-17,共4页
Academic Journal of Guangzhou Medical College
关键词
前列腺特异性膜抗原
前列腺肿瘤
良性前列腺增生
诊断
prostate specific membrane antigen
prostate carcinoma
benign prostate hypertrophy
diagnosis
